Catalog No.
DVV00331
Expression system
Mammalian Cells
Species reactivity
SARS-CoV-2 (2019-nCoV)
Host species
Human
Isotype
IgG1
Clonality
Monoclonal
Target
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P0DTC2
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
DH1047
Conformational Landscaping and Dynamic Mutational Profiling of Binding Interactions and Immune Escape for Broadly Neutralizing Class I Antibodies with SARS-CoV-2 Spike Protein: Distributed Binding Hotspot Networks Underlie Mechanism of Viral Resistance Against Existing Variants., PMID:40510568
Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates., PMID:40498855
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base., PMID:40447603
Cross-reactive sarbecovirus antibodies induced by mosaic RBD nanoparticles., PMID:40402246
Exploring Diverse Binding Mechanisms of Broadly Neutralizing Antibodies S309, S304, CYFN-1006 and VIR-7229 Targeting SARS-CoV-2 Spike Omicron Variants: Integrative Computational Modeling Reveals Balance of Evolutionary and Dynamic Adaptability in Shaping Molecular Determinants of Immune Escape., PMID:40376091
Computationally designed proteins mimic antibody immune evasion in viral evolution., PMID:40345199
Cryo-EM reveals conformational variability in the SARS-CoV-2 spike protein RBD induced by two broadly neutralizing monoclonal antibodies., PMID:40330036
AI designed, mutation resistant broad neutralizing antibodies against multiple SARS-CoV-2 strains., PMID:40319133
A SARS-CoV and SARS-CoV-2 RBD Heterodimer Vaccine Candidate., PMID:40317517
Self-assembled epitope-based nanoparticles targeting the SARS-CoV-2 spike protein enhanced the immune response and induced potential broad neutralizing activity., PMID:40270771
A Self-Assembled Nanovaccine with BA.4/5 Receptor-Binding Domain and CpG Oligodeoxynucleotides Induces Broad-Spectrum Neutralization against SARS-CoV-2 Omicron Subvariants., PMID:40265996
Intranasal parainfluenza virus-vectored vaccine expressing SARS-CoV-2 spike protein of Delta or Omicron B.1.1.529 induces mucosal and systemic immunity and protects hamsters against homologous and heterologous challenge., PMID:40258004
Structural basis and mode of action for two broadly neutralizing nanobodies targeting the highly conserved spike stem-helix of sarbecoviruses including SARS-CoV-2 and its variants., PMID:40215243
Chimeric receptor-binding domain vaccine design and sequential immunization enhanced broadly neutralizing antibody responses against COVID-19., PMID:40213557
A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein., PMID:40184253
Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses against SARS-CoV-2 variants in animal models., PMID:40165947
Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escape., PMID:40153503
Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants., PMID:40135898
Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study., PMID:40109335
Rapid clonal expansion and somatic hypermutation contribute to the fate of SARS-CoV-2 broadly neutralizing antibodies., PMID:40073246
Intranasal Administration of Bivalent RBD Nanoparticles Elicits Strong Systemic Responses That Effectively Block Distal Dissemination of COVID-19., PMID:40059333
Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection., PMID:40050417
[Construction of a human anti-SARS-CoV-2 scFv library and identification of broad-spectrum neutralizing antibodies]., PMID:40047475
Dynamics of spike-specific neutralizing antibodies across five-year emerging SARS-CoV-2 variants of concern reveal conserved epitopes that protect against severe COVID-19., PMID:40040708
Pan-Variant SARS-CoV-2 Vaccines Induce Protective Immunity by Targeting Conserved Epitopes., PMID:40014015
Epimaps of the SARS-CoV-2 Receptor-Binding Domain Mutational Landscape: Insights into Protein Stability, Epitope Prediction, and Antibody Binding., PMID:40001604
Quantitative Characterization and Prediction of the Binding Determinants and Immune Escape Hotspots for Groups of Broadly Neutralizing Antibodies Against Omicron Variants: Atomistic Modeling of the SARS-CoV-2 Spike Complexes with Antibodies., PMID:40001552
Epitope-focused vaccine immunogens design using tailored horseshoe-shaped scaffold., PMID:39966941
Structural prediction of chimeric immunogen candidates to elicit targeted antibodies against betacoronaviruses., PMID:39908344
Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineering., PMID:39908098
Mixed lipopeptide-based mucosal vaccine candidate induces cross-variant immunity and protects against SARS-CoV-2 infection in hamsters., PMID:39849995
Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques., PMID:39847599
Retrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive., PMID:39841142
S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines., PMID:39830514
A type of cryptic epitope-binding antibody on SARS-CoV-2 RBD retains the neutralization against SARS-CoV-2 variants and sarbecoviruses., PMID:39828152
IgA class switching enhances neutralizing potency against SARS-CoV-2 by increased antibody hinge flexibility., PMID:39828085
A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5., PMID:39800731
Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodies., PMID:39746041
Engineering mRNA vaccine with broad-spectrum protection against SARS-cov-2 variants., PMID:39742790
Structural Immunology of SARS-CoV-2., PMID:39731211
Enhanced antibody response to the conformational non-RBD region via DNA prime-protein boost elicits broad cross-neutralization against SARS-CoV-2 variants., PMID:39727342
High-throughput specificity profiling of antibody libraries using ribosome display and microfluidics., PMID:39689695
Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo., PMID:39621673
Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variants., PMID:39612651
Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV., PMID:39589795
ACE2-independent sarbecovirus cell entry can be supported by TMPRSS2-related enzymes and can reduce sensitivity to antibody-mediated neutralization., PMID:39536058
Exploring B-cell epitope conservation and antigenicity shift in current COVID-19 variants: Analyzing spike-antibody interactions for therapeutic uses., PMID:39531907
Engineered bispecific antibodies with enhanced breadth and potency against SARS-CoV-2 variants and SARS-related coronaviruses., PMID:39520579
A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation., PMID:39494911
Engineering a SARS-CoV-2 Vaccine Targeting the Receptor-Binding Domain Cryptic-Face via Immunofocusing., PMID:39463836
For research use only. Not for human or drug use.
